Melatonin Receptors

Melatonin is a endogenous hormone that acts as an agonist at melatonin receptors MT1 and MT2.

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 (IC50 =28.5 ?? 8.55 pM)and MT2 (20.1 ?? 9.25 pM)receptors and selectivity over the MT3 receptor.

Prazosin HCl is an α1 and α2B-adrenoceptor antagonist. Also a potent antagonist at the melatonin MT3 receptor (Ki = 10.2 nM).

Tasimelteon is a melatonin MT1 and MT2 receptor agonist.

Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist.

AP1189 is a biased agonist at receptors MC1 and MC3. AP1189 reduced cytokine release, an effect reliant on both MC1 and MC3 as evident from the use of Mc1r(-/-) and Mc3r(-/-) macrophages.

ACH-000143 is a potent and peripherally preferred melatonin receptor agonist.

Luzindole, also known as N-0774, and N-acetyl-2-benzyltryptamine, is a melatonin receptor antagonist that preferentially targets MT1B over MT1A (Ki values are = 10-27 and 158-513 nM, respectively).

Piromelatine is a selective agonist for the melatonin MT1 and MT2 receptors, alongside its activity as a serotonin 5-HT1A/5-HT1D agonist and a 5-HT2B antagonist. This compound exhibits various biological activities, including promoting sleep, providing analgesic effects, and demonstrating anti-neurodegenerative, anxiolytic, and antidepressant properties. Additionally, Piromelatine shows inhibitory effects on pain-associated channels such as P2X3, TRPV1, and Nav1.7, making it a valuable tool for research in neuropharmacology and pain management.

UCM 608 is a high-affinity agonist of melatonin (MT) receptors, specifically targeting MT1 and MT2 with pKi values of 10.7 and 10.4, respectively. This compound exhibits significant biological activity in modulating melatonin signaling pathways, making it valuable for research applications related to sleep regulation, circadian rhythm studies, and potential therapeutic interventions for sleep disorders.

N-Acetyltryptamine is a partial agonist for melatonin receptors, particularly in retinal tissues. It plays a crucial role in modulating circadian rhythms and has applications in studying melatonin signaling pathways. Additionally, N-Acetyltryptamine is utilized to assess serotonin N-acetyl transferase activity in biochemical research.

S-20928 is a selective antagonist of melatonin receptors, inhibiting melatonin’s binding to these receptors. This compound has been demonstrated to enhance the 2-Deoxy-D-glucose (2DG)-induced elevation of blood glucose and glucagon levels in rat brain studies. S-20928 is relevant for research on metabolic regulation and the physiological effects of melatonin modulation.

Melatonin Receptor Agonist 1 is a selective agonist for the melatonin receptors, specifically showing Ki values of 108 nM for MT2 and 1140 nM for MT1. This compound is useful for studying melatonin signaling pathways and their roles in various physiological processes, including sleep regulation and circadian rhythm modulation. Its potential applications in research extend to areas such as neurobiology, sleep disorders, and the effects of melatonin on metabolic processes.

6-Chloromelatonin is a highly effective melatonin receptor agonist that exhibits enhanced metabolic stability compared to melatonin. It demonstrates strong binding affinity to the MT1 receptor, competing with both [3H]-melatonin and 2-[125I]-iodomelatonin (pKi = 8.9 and 9.1, respectively). Additionally, 6-Chloromelatonin shows significant competition for [3H]-melatonin binding at MT2 receptors with a pKi value of 9.77. This compound is valuable for research in sleep regulation, circadian rhythms, and neuropharmacology.

GR 196429 is a melatonin receptor agonist primarily targeting the MT1 subtype. This compound has been shown to promote sleep and modify circadian rhythms, in addition to stimulating melatonin release in murine models. It serves as a valuable tool for investigating sleep disorders and the biological mechanisms underlying circadian regulation.

(R)-Ramelteon is an orally active compound that serves as an inactive isomer of melatonin receptors 1 and 2. It has been studied for its potential role in modulating sleep patterns and may provide insight into the mechanisms underlying sleep regulation. This compound is of particular interest in research applications related to sleep disorders and circadian rhythm studies.

GR 128107 is a competitive antagonist of melatonin receptors, exhibiting a high binding affinity with a pKi of 9.6. This compound is utilized in research to investigate the physiological roles of melatonin signaling pathways and its involvement in circadian rhythm regulation. GR 128107 can aid in the exploration of sleep disorders, neurodegenerative diseases, and the modulation of various neurochemical processes.

Nedemelteon is a melatonin receptor agonist that selectively binds to MT1 and MT2 receptors, playing a crucial role in regulating circadian rhythms and sleep-wake cycles. Its primary biological activity includes promoting sleep onset and improving sleep quality, making it valuable for research on sleep disorders and related conditions. This compound is utilized in studies investigating the therapeutic potential of melatonin modulation in various neurological and psychological contexts.

Pareptide monohydrochloride is a stable analogue of melanotropin-inhibiting factor (MIF) that primarily targets melatonin receptors. This compound exhibits significant biological activity in modulating melatonin signaling pathways, making it a valuable tool for research in circadian rhythms and sleep disorders. Its application spans various studies focused on neurobiology, pharmacology, and the mechanisms of sleep regulation.